Contact
Please use this form to send email to PR contact of this press release:
GSK announces data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes
TO:
Please use this form to send email to PR contact of this press release:
GSK announces data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes
TO: